Dr. Berdeja on Dosing JNJ-4528 in Relapsed/Refractory Multiple Myeloma
Jesus G. Berdeja, MD, discusses the dosing of the investigational CAR T-cell product JNJ-4528 in patients with relapsed/refractory multiple myeloma.
Dr. Berdeja on Updated CARTITUDE-1 Results With JNJ-4258 in Multiple Myeloma
Jesus G. Berdeja, MD, discusses updated safety results from the ongoing phase 1b/2 CARTITUDE-1 trial (NCT03548207) with the CAR T-cell therapy JNJ-4528 in multiple myeloma.
